Our business development strategy is to generate value by establishing clinical proof of concept of our preclinical product candidates for a number of highly valuable, unmet therapeutic areas and to form strategic partnerships for later stage drug development and commercialization efforts. In our partnerships we seek to retain downstream product rights to continually drive value for future corporate transactions.

Calistoga Pharmaceuticals is also interested in acquiring additional assets to potentially accelerate and broaden our pipeline of PI3K-targeted therapeutic candidates